Poorman, Of course that was just a guess and not one that included PRs for regulatory package acceptances. My guess there is that UK is pending and US and/or EMEA are not far behind, or anything about partnership/financing deals, uplisting or anything else financial sector. You would know much better about that stuff.
When things come together in time, they look conspicuous to me. Although wrong about ASCO, it looked suspiciously like all roads were leading to ASCO. LLs schedule looked so much like ASM was not the event it was the kick-off. A case must be made before the 15 minute world stage that is ASCO Late Breaker. Interestingly, both the CME (which actually did deliver one surprise) and the Mt.Sinai talks still fit right in with that picture. Utah to Mt. Sinai was progression of the clinical argument for DCVAX to assumption that everything begins with DCVAX. This was open peer review among the best hosted as guest and the message is clear. The message is not only accepted but being supported openly by everyone. From the American Academy of Medicine to the Society for Neurooncology. From LA to NYC with stops in SF, Seattle and Salt Lake along the way. I am personally curious why Chicago or at least Cleveland has not been a station of record yet (We are the second biggest region, not the third. Dallas, Houston, Atlanta or Raleigh should show up too) because it then boards a plane and hops across the pond with stops in London, Amsterdam, Munich, and Zurich. All signs post that the benevolent monarchies of Scandinavia and their National Registries will climb on if they haven’t already. France, Spain and Itlay are all worth a visit too. With Big Brother or the Queen comes Canada and Australia and with one comes Isreal. Check, check doible check...
So now we have some other series as an anchor. I don’t think ESMO is that anchor, but I do think ESMO aligns spatially in time to fit into the ship. A publication submitted in April-May should not reasonably be expected to be published before September. A turn around of a United Kingdom Package with NICE review may also line up nicely to fit Flipper’s explanation of events. FDA has a record of just under 3 months from package acceptance to approval, but that was for an orphan disease with a fatal outcome and there was an early efficacy signal that caused early termination after all placebos were immediately shifted to treatment. In this case, however, mortality is not how things are measured and to continue on would be barbaric.
DCVAX IS safe and feasible to add to the STANDARD OF CARE.
AI
